Mission of R&D Centers
Development
Development of the innovative biological medicines
- Biosimilar and new biologics based on Open collaboration with Expert and Doctors
- Necessary medicines in local country
- Reverse Innovation
Contribution
Contribution for Indonesia biopharmaceuticals
- Support a new education program in the cooperation with Faculty of Pharmacy
- Share Lab. instruments for Professor/students who studying in the field of Biotechnology
- Make an experts for Biological area
Respected
Respected Research Institute to all Employees, Partners, Customers
- Everyone Win – Win
- Provide the right information & optimized solution to the customers
- Priority to the growth of employee’s than the development of the company
Vision of R&D Centers
Various facilities that support Daewoong Indonesia's vision "Improving the quality of human life by developing treatments for chronic diseases and rare diseases"
R&D Portfolio
New drugs
- Expansion of launching contury of Fexuclue and expansion of its pipeline
- Launching Envlo and expansion of its pipeline
- Strengthen the portfolio of autoimmune, fibrosis, metabolic and cancer treatments
- New modality in drug discovery (mRNA, TPD)
Biologics
- Development of stem cell therapy for intractable and rare diseases
- Expansion of Jeuveau (Nabota)’s indications
- EGF Line ext. Expansion of EGF pipeline
- Development of Bioconvergence medical devices
- Identification of age-related candidate
New products
- Launch Luphere Depot in the US and Japanese market
- Expansion of differentiation generics and incrementally modified drugs based on DDS platform technology
- The global Release of self-developed medicines
C&D (Connect & Development)
- Focus on cell & gene therapy development through Open Collaboration
- Expansion of therapeutic areas such as anti-cancer / metabolism diseases / immuno-diseases / vaccine